Publicaciones (20) Publicaciones de Maria Teresa Perez Martinez

2024

  1. Colchicine in acute heart failure: Rationale and design of a randomized double-blind placebo-controlled trial (COLICA)

    European Journal of Heart Failure

  2. Functional Significance in Spontaneous Recanalization of a Coronary Thrombus

    JACC: Case Reports, Vol. 29, Núm. 16

  3. Withdrawal of drug therapy in responders to cardiac resynchronization therapy: rationale and design of the REMOVE trial

    Revista Espanola de Cardiologia, Vol. 77, Núm. 10, pp. 851-858

2021

  1. Colchicine in recently hospitalized patients with COVID-19: A randomized controlled trial (COL-COVID)

    International Journal of General Medicine, Vol. 14, pp. 5517-5526

  2. Contemporary Management of Severe Symptomatic Aortic Stenosis

    Journal of the American College of Cardiology, Vol. 78, Núm. 22, pp. 2131-2143

2020

  1. Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 22, Núm. 8, pp. 1424-1437

  2. Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 22, Núm. 1, pp. 92-102

  3. Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 22, Núm. 8, pp. 1378-1389

2019

  1. Acute heart failure congestion and perfusion status – impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 21, Núm. 11, pp. 1338-1352

  2. Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world

    European Journal of Heart Failure, Vol. 21, Núm. 11, pp. 1383-1397

2018

  1. Noncardiac Production of Soluble ST2 in ST-Segment Elevation Myocardial Infarction

    Journal of the American College of Cardiology

  2. Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry

    JACC: Heart Failure, Vol. 6, Núm. 6, pp. 452-462

  3. Pulmonary Production of Soluble ST2 in Heart Failure

    Circulation. Heart failure, Vol. 11, Núm. 12, pp. e005488

  4. Short-term Serial Measurement of Galectin-3 in Hospitalized Patients With Acute Heart Failure

    Revista Espanola de Cardiologia, Vol. 71, Núm. 5, pp. 401-402

  5. Testosterone Replacement Therapy in Deficient Patients With Chronic Heart Failure: A Randomized Double-Blind Controlled Pilot Study

    Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 23, Núm. 6, pp. 543-550

2016

  1. Clinical relevance of sST2 in cardiac diseases

    Clinical Chemistry and Laboratory Medicine, Vol. 54, Núm. 1, pp. 29-35

  2. Factor de transcripción TBX1 en el remodelado cardiaco asociado al infarto de miocardio

    Revista Espanola de Cardiologia, Vol. 69, Núm. 11, pp. 1042-1050

2015

  1. Prognostic Value and Kinetics of Soluble Neprilysin in Acute Heart Failure. A Pilot Study.

    JACC: Heart Failure, Vol. 3, Núm. 8, pp. 641-644

2013

  1. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 15, Núm. 10, pp. 1173-1184

  2. Involvement of ferritin heavy chain in the preventive effect of metformin against doxorubicin-induced cardiotoxicity

    Free Radical Biology and Medicine, Vol. 57, pp. 188-200